For individuals with neuromyelitis optica spectrum disorder (NMOSD) or myelin oligodendrocyte glycoprotein associated disease (MOGAD), long-term treatment with rituximab is associated with reduced annualized relapse rates.
Why this matters?
NMOSD is a relapsing central nervous system disorder, primarily affects optic nerves and spinal cord, with an additional disease subset known as and MOGAD. Treatment is recommended due to high risk of relapse and neurological disability.
Data on the effectiveness and safety of long-term rituximab use in patients with NMOSD and MOGAD is limited but necessary to provide optimal care for these patients.